Tularemia in a pregnant patient calls for careful antimicrobial selection. Pregnancy significantly constrains which agents are appropriate, making the choice of first-line therapy — and any contingency options — highly specific to this clinical context.
For pregnant women with any form of tularemia, specific fluoroquinolones or an aminoglycoside are the recommended first-line antimicrobials. Drug selection must account for both pathogen coverage and fetal safety, and the availability of agents at the time of treatment can further shape the clinical decision.
When established first-line and alternative antimicrobial options are unavailable or contraindicated, an additional agent may be considered — but only after the causative pathogen subspecies has been confirmed. The full protocol defines which agent applies, under exactly which conditions, and how the complete regimen is structured.
For pregnant women with any form of tularemia, fluoroquinolones (i.e., ciprofloxacin or levofloxacin) or gentamicin are recommended for first-line treatment.
In addition to the first-line and alternative treatment options (Table 3), if supplies of these antimicrobial drugs are unavailable or patients have contraindications to these options, azithromycin 500 mg orally or IV for 10 days can be considered if the pathogen released is known to be F. tularensis subspecies tularensis (Type A) or F. tularensis subspecies holarctica (Type B) biovar I or biovar japonica.
View source ↗